
Global & Greece Cancer Therapeutics Market to 2031
Description
Greece has seen a significant rise in cancer cases, positioning the country as a key area for healthcare investment and innovation. According to the European Cancer Information System 2023, over 63,000 new cancer cases were reported in 2022, with the disease causing more than 32,000 deaths. Among men, prostate, lung, and colorectal cancers are the most commonly diagnosed, while breast cancer leads among women, followed by colorectal and lung cancers.
In response to this growing health concern, the Greek government has launched various initiatives aimed at enhancing cancer care and improving access to treatments. In October 2024, the Ministry of Health, in collaboration with the National and Kapodistrian University of Athens (EKPA), launched the National Cancer Plan for 2024–2028. This plan is designed to align with European Union objectives, particularly Europe’s Beating Cancer Plan, and integrates the latest scientific developments to ensure a cohesive, patient-centered approach to oncology care.
Private sector involvement is also contributing to market growth. In July 2024, Daiichi Sankyo established a new oncology division affiliate in Athens, demonstrating the company’s commitment to supporting cancer patients across Europe. Additionally, Greece’s strategic location within Europe offers valuable opportunities for cross-border research partnerships, further driving the expansion of the country’s cancer therapeutics market.
In response to this growing health concern, the Greek government has launched various initiatives aimed at enhancing cancer care and improving access to treatments. In October 2024, the Ministry of Health, in collaboration with the National and Kapodistrian University of Athens (EKPA), launched the National Cancer Plan for 2024–2028. This plan is designed to align with European Union objectives, particularly Europe’s Beating Cancer Plan, and integrates the latest scientific developments to ensure a cohesive, patient-centered approach to oncology care.
Private sector involvement is also contributing to market growth. In July 2024, Daiichi Sankyo established a new oncology division affiliate in Athens, demonstrating the company’s commitment to supporting cancer patients across Europe. Additionally, Greece’s strategic location within Europe offers valuable opportunities for cross-border research partnerships, further driving the expansion of the country’s cancer therapeutics market.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Greece Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Greece Cancer Therapeutics Market – Analysis
- 6.1 Greece Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Greece Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Greece Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Greece Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Greece Cancer Therapeutics Market Analysis – by Indications
- 8.1 Greece Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Greece Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Greece Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Greece Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Greece Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Greece Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Greece Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Greece Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Greece Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Greece Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Greece Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Greece Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Greece Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.